CIAM
AVIR icon

Caitong International Asset Management’s Atea Pharmaceuticals AVIR Stock Holding History

Caitong International Asset Management’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$112 Buy
24
+22
+1,100% +$109 ﹤0.01% 2149
2026
Q1 		$11 Buy
+2
New +$9 ﹤0.01% 2132
2025
Q1 		– Sell
-479
Closed -$1.6K – 2172
2024
Q4 		$1.6K Buy
+479
New +$1.59K ﹤0.01% 1214

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Caitong International Asset Management's AVIR Position: Q2 2026 in Review

Caitong International Asset Management increased its Atea Pharmaceuticals (AVIR) stake by 1,100% in Q2 2026, buying an estimated $109 and bringing the position to 24 shares worth $112. The position accounts for ﹤0.01% of the portfolio, ranked #2149.

Caitong International Asset Management first reported a position in AVIR in Q4 2024 and has held it in 3 quarters since. The position peaked at $1.6K in Q4 2024. 124 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

  • Caitong International Asset Management held 24 shares of Atea Pharmaceuticals worth $112 as of Q2 2026.
  • Caitong International Asset Management bought 22 Atea Pharmaceuticals shares in Q2 2026, an estimated $109.
  • Atea Pharmaceuticals made up ﹤0.01% of Caitong International Asset Management's portfolio in Q2 2026, its #2149 holding.
  • Caitong International Asset Management first reported a position in Atea Pharmaceuticals in Q4 2024 and has held it in 3 quarters since.
  • Caitong International Asset Management's Atea Pharmaceuticals position peaked at $1.6K in Q4 2024.
  • 124 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on Caitong International Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.